Home > Cardiology > ACC 2021 > Electrophysiology > Favourable outcomes with transcatheter atrial appendage occlusion

Favourable outcomes with transcatheter atrial appendage occlusion

Presented By
Dr Matthew Price, Scripps Clinic, USA
Conference
ACC 2021
Trial
PROTECT AF, PREVAIL
Real-world data from the National Cardiovascular Data Registry (NCDR) left atrial appendage occlusion (LAAO) registry showed a decrease in thromboembolic events 1 year after receiving a WATCHMAN implant [1]. These 1-year clinical outcomes suggest a favourable alternative to anticoagulants for patients with non-valvular atrial fibrillation who are unable to take oral anticoagulants. The WATCHMAN device is a permanent device that is implanted into the left atrial appendage to prevent clot formation. It is used as an alternative to oral anticoagulant therapy for stroke prevention in atrial fibrillation for patients in whom oral anticoagulants are contraindicated. It was approved by the FDA in 2015 based upon favourable data from the PROTECT AF (n=463 implants) and PREVAIL (n=269 implants) trials [2,3]. It has also been approved for Medicare/Medicaid coverage in the US, but the eligibility criteria to qualify for reimbursement differ from the inclusion criteri...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on